TXG
10x Genomics, Inc.15.71
-0.05-0.32%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Q&A clarifies FLEX offset, clinical timeline
Q&A unpacked 2026 guidance, pinpointing flat Chromium consumables as FLEX APEX's 30%+ Q4 reaction surge offsets pricing headwinds from switches and mix. Xenium powered all spatial consumables growth; Visium flatlined. Management detailed clinical push with CLIA lab eyed for early 2027 startup in oncology/autoimmune, minimal P&L impact. Biopharma translational ramp targets half revenue long-term. CapEx constraints hit high-end gear hardest, yet competition shrugged off. FLEX adoption accelerates. Investors eye translational traction amid steady caution.
Key Stats
Market Cap
1.99BP/E (TTM)
-Basic EPS (TTM)
-0.63Dividend Yield
0%Recent Filings
10-K
FY2025 results
10x Genomics grew revenue 5% to $642.8M in FY2025 ended December 31, 2025, with consumables up 3% to $507.2M on Spatial strength (+19%) despite Single Cell dip (-2%), while instruments fell 39% to $56.8M from pricing and volume shifts. Q4 momentum showed Spatial consumables accelerating, driving gross margin to 69% via lower royalties and warranty costs, though inventory write-downs rose. Net loss narrowed to $43.5M from $182.6M, fueled by $49.9M patent settlement gains and $136M operating cash flow. Cash hit $523M; Scale Bio acquisition adds single-cell tech with $24.6M contingent liability. Yet funding cuts threaten academic sales.
8-K
Q4 revenue up 1%, FY guides flat
10x Genomics posted Q4 revenue of $166M, up 1% year-over-year, and full-year $642.8M, up 5% but down 2% excluding $44.1M litigation settlements. Gross margins rose to 69%, operating loss shrank to $61M from $194.6M, cash swelled to $523.4M. New partnerships fuel AI-cancer datasets. Guides 2026 revenue $600M-$625M. Losses narrowed sharply.
8-K
Preliminary Q4 revenue $166M
10x Genomics released preliminary Q4 2025 results on January 11, 2026, showing $166M revenue, up 1% year-over-year but with instruments down sharply to $15.5M amid macro headwinds. Full-year revenue hit $642.8M including $44.1M litigation settlements; core revenue fell 2%, yet Spatial consumables surged 19% to $144M while Chromium instruments topped 6,400 sold. Balance sheet strengthened to $520M cash.
8-K
CLO retires; internal successor named
10x Genomics' Chief Legal Officer Eric Whitaker announced retirement effective January 1, 2026, after eight years, transitioning to Strategic Counsel for ongoing matters. VP Intellectual Property and Litigation Dr. Randy Wu succeeds him, bringing nearly a decade at the firm plus elite credentials from Stanford and UCSF. Leadership stays steady. Smooth handoff preserves legal expertise.
10-Q
Q3 FY2025 results
10x Genomics posted Q3 revenue of $149M, down 2% y/y yet up sharply from Q2's net income swing to a $27.5M net loss—milder than last year's $35.8M. Gross margin slipped to 67% on product mix shifts and inventory write-downs, while operating loss narrowed to $32.2M from $41.5M y/y via 14% lower R&D and 8% slimmer SG&A post-restructuring. Cash swelled to $433M, fueled by $95M nine-month operating cash flow; closed Scale asset buy in August for $9.2M cash plus $13.5M stock, booking $51.6M developed technology. Litigation drags on.
IPO
Website
Employees
Sector
Industry
A
Agilent Technologies, Inc.
139.19-1.41
APDN
Applied DNA Sciences, Inc.
5.62+1.35
BNGO
Bionano Genomics, Inc.
1.57+0.03
BRGX
BioRegenx, Inc
0.02+0.00
DGX
Quest Diagnostics Incorporated
178.66-5.45
ILMN
Illumina, Inc.
131.56-3.36
LAB
Standard BioTools Inc.
1.49-0.02
QTRX
Quanterix Corporation
7.36-0.05
TECH
Bio-Techne Corp
57.44-1.25
WGS
GeneDx Holdings Corp.
141.72-8.89